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The risks for transplant outcomes associated with baseline viral serostatus in kidney transplant 
recipients (KTR) on sirolimus have not been widely studied. 
Methods: 
We performed a cohort-study of 61 590 adult KTR in 2000-2013. We used Cox regression 
models to determine the adjusted hazard ratio (aHR) of patient death, death-censored graft loss 
and posttransplant malignancy associated with the baseline serostatus [+ or -: Hepatitis B core 
(HBc), Hepatitis C (HCV), Epstein Barr (EBV) or Cytomegalovirus (CMV)] in KTR on 
sirolimus+mycophenolate (SRL+MPA) or sirolimus+tacrolimus (SRL+Tac), relative to the 
control-regimen: tacrolimus+mycophenolate (Tac+MPA) 
Results: 
Compared with Tac+MPA, SRL+MPA and SRL+Tac were associated with higher risks of 5-year 
mortality [(aHR=1.41 95%CI= 1.23-1.60) and (aHR= 1.59, 95% CI= 1.38-1.83), respectively) 
and death-censored graft loss, [(aHR= 1.41, 95% CI= 1.24-1.60) and (aHR= 1.38, 95% CI= 1.21-
1.57), respectively]. In KTR with negative pretransplant EBV, CMV, HBc or HCV serostatus, 
SRL+MPA not SRL+Tac was associated with a lower risk of posttransplant malignancy 
compared with control [(aHR=0.27, 95%CI=0.10-0.72 ), (aHR=0.61, 95%CI=0.43-0.88), 
(aHR=0.79, 95%CI=0.64-0.97) and (aHR=0.80, 95%CI=0.65-0.98); respectively for SRL+MPA] 
and [(aHR=0.98, 95%CI=0.52-1.80), (aHR=0.69, 95%CI=0.46-1.06), (aHR=0.83, 95%CI=0.66-
1.06) and (aHR=0.85, 95%CI=0.67-1.07); respectively for SRL+Tac]. In KTR with positive 
serostatus to any of the above viruses, SRL+MPA or SRL+Tac was not associated with a 









Compared with Tac+MPA, SRL-regimens were associated with higher risks for patient death 
and graft loss; although, SRL+MPA was associated with a lower risk for posttransplant 











A primary or reactivation viral infection after kidney transplantation can have serious impact on 
patient and graft outcomes. Direct effects of viral infections can range from nonspecific systemic 
syndromes to tissue invasive diseases involving the allograft or other organs [1,2]. By further 
impairment of host immune defenses, some viruses can promote other opportunistic infections 
[2,3]. Indirect effects of viral infections include alteration of surface human leukocyte antigen 
expression and release of growth factors and chemokines that can lead to acute and chronic 
rejection [2, 4, 5, 6]. Viral infections can directly promote posttransplant malignancies by 
causing dysregulation in cellular proliferation-antiproliferation pathways [2, 6]. 
 
Potent immunosuppression which has reduced graft rejection rates and improved graft survival 
rates after kidney transplantation can promote viral infections which by various mechanisms can 
contribute to allograft failure and recipient morbidity and mortality [1]. The impairment of 
immune control of viral oncogenes by immunosuppression can also lead to posttransplant 
malignancies [2, 6, 7-18]. Interestingly, some animal and human studies have shown that a class 
of immunosuppressant drugs, the mammalian target of rapamycin (mTor) inhibitors, also possess 
anti-viral and anti-neoplastic properties [18,35,20,21,22].  
 
Laboratory studies have shown an important role for mTOR signaling in the pathogenesis of 
fungal, parasitic and viral infections [23, 24] and in oncogenesis [ 25-28]. Accumulating 
evidence from clinical studies suggest that in transplant recipients, mTOR-inhibitors participate 
in the inhibition of replication and clearance of Polyoma BK virus [29], reduce the incidence of 
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(HCV) recurrence [31]. Similarly, clinical studies have shown the anti-cancer properties of 
mTOR-inhibitors. Kahan et al. reported that compared with other immunosuppressants, mTOR-
inhibitors were associated with lower incidence rates for all malignancies, post-transplant 
lymphoproliferative diseases (PTLD), renal cell carcinomas, and skin cancers [22]. An 
observational study by Kauffman and colleagues showed that mTOR-inhibitor use was 
associated with a 56% reduction in the risk for de novo solid cancer after kidney transplantation 
[32]. A US database study showed that with 1 exception, the incidence of cancer was decreased 
by 26% with the use of sirolimus compared with nonsirolimus immunosuppression [33]. The 
data from the clinical trial, CONVERT study showed that (calcineurin inhibitor) CNI conversion 
to sirolimus compared to CNI continuation was associated with a significant reduction in the 
incidence of skin cancers and total malignancies in kidney transplant recipient [34,35]. Hence, an 
immunosuppressant that inhibits both viral activation and oncogenesis would provide additional 
unique benefits to organ transplant recipients. Unfortunately, association between transplant 
outcomes and the effects of pretransplant viral serology and posttransplant mTor inhibitor 
regimens have not been widely explored. Therefore, using SRTR data on 61 590 kidney 
transplants in the US from 2003 through 2013, we conducted this observational cohort study in 
order to investigate the risks for post-transplant patient death, graft loss and post-transplant 
malignancy associated with sirolimus regimens and pre-transplant viral serostatus of KTR. Our 
findings presented in this manuscript could provide the basis for utilizing baseline serology as an 
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Patients and Methods 
 
This study which used data from the Scientific Registry of Transplant Recipients (SRTR) and 
was approved by the University of Florida Institutional review board. The SRTR system includes 
data on all donor, wait-listed candidates, and transplant recipients in the US, submitted by the 
members of the Organ Procurement and Transplantation Network (OPTN), and has been 
described elsewhere. The Health Resources and Services Administration provides oversight to 
the activities of the OPTN and SRTR contractors. 
 
A retrospective cohort design was used to investigate outcomes associated with 2 common 
sirolimus regimens in relation to the pretransplant viral serostatus of adult kidney-only transplant 
recipient (KTR) in the United States from January 1, 2000 through December 31, 2013. KTR 
who survived the first transplant year free of cancer or graft loss, and met the inclusion criteria 
were included in the study. Follow-up started after the 12
th
 month of kidney transplant, until the 
earliest of the following: 1. End of fifth transplant year, 2. Re-transplantation, 3. Death, or 4. end 
of SRTR follow-up. Endpoints for this study included patient death, death-censored graft loss, 
and post-transplant malignancy (consisting of de novo tumors and posttransplant 
lymphoproliferative disorders censored for death or graft loss), (21). Analyses focused on the 
association of outcomes to the interactions between HBc, HCV, EBV or CMV pretransplant 
antibody serostatus and sirolimus and mycophenolate with/without steroid (SRL+MPA) or 






Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
8 
 
Based on SRTR files, the following pretransplant viral antibody serostatus classified as positive 
(+) or negative (-), were included for analysis in this study: Hepatitis B core (HBc), Hepatitis C 
virus (HCV), Cytomegalovirus (CMV), and Epstein Barr Virus (EBV). 
 
KTR cohorts were formed based on the immunosuppression regimen continuously used for a 
minimum duration of 6 months immediately before and including the twelfth-month 
posttransplant follow-up. Based on the SRTR immunosuppression follow-up files, KTR were on 
the same regimen at discharge, 6
th
 month and 12
th
 month follow-up, or only at the 6
th 
month 
and12th month follow-up, with a different regimen at discharge. The study cohorts consisted of 
KTR on sirolimus and mycophenolate mofetil or sodium with/without steroids (SRL+MPA) and 
sirolimus and tacrolimus with/without steroids (SRL+Tac) regimens. The reference or control 
cohort consisted of KTR on tacrolimus and mycophenolate with/without steroids (Tac+MPA). 
Use of steroids was disregarded in cohort stratification, but was corrected for in the multivariable 
models. Due to their distinctly different management requirements, recipients with positive 
human immunodeficiency virus (HIV) serology were excluded from this study Also excluded 
from this study were KTR who had a malignancy, died or lost their allograft within the first 12 
months of transplant; recipients of nonrenal organ transplant; and, those with missing data on 
baseline serology or maintenance immunosuppression at pertinent follow-up periods. 
 
From among the KTR who would have met the study inclusion criteria except for the duration of 
sirolimus regimen use specified above, the following cohorts were formed for additional 
analyses of outcomes: 1. KTR who were on a sirolimus regimen at discharge and the 6
th
 month 
follow-up only, with different regimens at 12
th
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sirolimus regimen either at discharge or the 6
th
 month follow-up only with different regimen/s at 
other relevant follow-up times, or at discharge and the 12
th






Baseline cohort characteristics were presented using means with standard deviations for 
continuous variables and proportions (percentages) for categorical variables. Differences in 
means and proportions were compared with the Student’s t test and Chi-square test, respectively. 
The viral serology statuses, and sirolimus regimens, and literature-based outcomes-specific risk 
factors (36), were used as independent co-variates in the main and sirolimus regimen x viral 
serostatus interaction Cox multivariable regression models (subsequently termed Cox models) 
for patient death, death-censored graft loss and malignancy occurrence censored for death or 
graft loss (21, 37-40) in the 4 years following the posttransplant month-12 follow-up, i.e. 5 years 
posttransplant. A co-variate for year of transplant after 2009 was included to adjust for any 
confounding influence on the study outcomes of the clinicians’ prescribing behavior as result of 
a Federal Drug Administration alert to all US physicians on June 2009 regarding the increased 
mortality associated with conversion of calcinuerin inhibitor-based immunosuppression to 
sirolimus [41]. Additional Cox regression analyses with the same outcomes and covariates as in 
the main study cohorts were performed on KTR who were on SRL+MPA or SRL+Tac within the 
first transplant year but did not meet the required duration of treatment specified for inclusion in 
the study. The unadjusted odds ratio for death in 5 years, after 1-year conditional survival, for 
each specific cause (infections, cardio-vascular diseases, malignancies or any organ failure) were 
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multivariable analyses, co-variates other than drug regimens or viral serostatuses were selected 
based on previously published studies [36]. Conformity of the Cox models with the 
proportionality of hazards assumption were verified by visually inspecting the complementary 
log-log survival plots for the primary explanatory variables and examining the Schoenfeld 
residual plots. The risk factors predictive of the continuous use of either SRL+MPA or SRL+Tac 
regimens vs. Tac+MPA in the study treatment period were assessed by multivariable logistic 
regression analysis. Results of the Cox or logistic regression models were reported as hazard 
ratio (HR) or odds ratio (OR), respectively with the 95% confidence interval (CI) for each 
covariate. All analyses were performed using SAS software, version 9.2 (SAS Institute, Inc., 
Cary, NC, USA). Statistical significance was based on a p-value < .05 and all confidence 
intervals used a 95% threshold.  
 
Results 
Study population and demographics 
We studied 61 590 adult kidney transplant cases from Jan 1, 2000 through December 31, 2013 
with conditional malignancy-free, patient and graft survival at 1 year. 2659 (4.3%) were on 
SRL+MPA, 2167 (3.5%) on SRL+Tac and 56 764 (92.2%) on Tac+MPA. The baseline 
characteristics of the study cohorts are shown in Table 1. The Hepatitis B core and CMV 
antibody seropositivity rates differed statistically among the groups but there were no significant 
differences in the antibody seropositivity to HCV and EBV among the cohorts, (Table 1). 
Utilization of T cell-depleting antibodies for induction was highest in the Tac+MPA cohort, 






Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
11 
 
Predictors of being maintained on sirolimus for at least 6 months immediately before and 
including the first transplant year  
The likelihood of being maintained on SRL+MPA or SRL+Tac instead of Tac+MPA was 
increased with African American recipient race and decreased with the following factors: CMV+ 
serostatus, older age, PRA>20%, transplantation year after 2009 and alemtuzumab induction 
(Table 2). Predictors of being maintained on SRL+MPA versus the other regimens were ECD 
kidney, coronary artery disease and male sex of transplant recipient. Obesity is associated with a 
lower likelihood of being maintained on SRL+Tac than the other regimens. Between the 2 
sirolimus regimens, the likelihood of being maintained on SRL+MPA instead of SRL+Tac was 
increased with the following factors: obesity, transplant after year 2009, alemtuzumab induction 
or first as opposed to repeat transplant (Table 2). 
 
Sirolimus regimen and viral serology as independent risk factors for outcomes 
The 5-year mortality, graft loss and posttransplant malignancy risks associated with the 
SRL+MPA and SRL+Tac regimens were analyzed with the Cox model using the Tac+MPA 
regimen as reference (Fig. 1,2,3). The mortality risks were higher in the SRL+Tac and 
SRL+MPA cohorts compared with the reference group  
 
[(HR=1.41, 95% CI=1.23-1.60; p<.001) and (HR=1.59, 95% CI=1.38-1.83; p<.001), 
respectively]. Compared with a negative serostatus, a positive HCV serostatus was associated 
with a higher mortality risk (HR=1.53, 95% CI=1.35-1.74; p<.001), while a positive EBV or 
CMV serostatus was associated with a lower mortality risk (HR=0.85, 95% CI=0.77-0.94; 
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was not associated with a significantly different mortality risk (HR=0.93, 95% CI=0.83-1.05; 
p=.23). The 5-year cause-specific death rates in the immunosuppression cohorts are depicted in 
Figure 4. Cardiovascular disease was the most common cause of death; and the unadjusted risks 
of death associated with the sirolimus regimens were not different from the reference regimen in 
any of the specific causes analyzed (organ failure, cardio-vascular disease, infection and 
malignancy), (Figure 4). 
 
Figure 2 shows that the SRL regimens were associated with higher 5-year death-censored graft 
loss (DCGL) risk than the Tac+MPA regimen [(SRL+MPA: HR=1.41, 95% CI=1.24-1.60; 
p<.001) and (Tac+SRL: HR=1.38, 95% CI=1.21-1.57; p<.001)]. Compared with a negative 
serostatus, a positive HCV serostatus was associated with a higher risk of graft loss (HR=1.50, 
95% CI=1.33-1.70; p<.001). The relative risks for DCGL associated with other viral serostatuses 
were not significant as shown in Fig. 2. 
 
Relative to the Tac+MPA regimen, the risk of death or graft loss-censored posttransplant 
malignancy (PTM) was 20 % lower with the SRL+MPA regimen and was not significantly 
different with the SRL+Tac regimen [(HR=0.80, 95% CI=0.65-0.98; p=.03) and (HR=0.82, 
95%CI=0.65-1.03; p=.09); respectively] Compared with a negative serostatus, a positive HCV 
serostatus was associated with a higher risk of PTM (HR=1.24, 95% CI=1.02-1.52; P=.02), while 
a positive HBc or CMV serostatus was associated with a lower risk of PTM [(HR=0.80 95% 
CI=0.68-0.95; p<.01) and (HR=0.82 , 95% CI=0.76-0.90; p<.001), respectively], (Figure 3). As 
depicted in Figure 3, ATG or alemtuzumab induction was associated with a higher PTM risk 
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CI=1.10-1.54; p=.002), respectively]. A steroid-containing maintenance regimen was associated 
with a higher risk of PTM than a steroid-free regimen (HR=1.14, 95% CI=1.04-1.25; p=.003). 
 
Sirolimus regimen and viral serology interaction as risk factor for outcomes 
After determining the adjusted risks independently associated with each of the sirolimus 
regimens and viral serology statuses, multiple Cox models were constructed to analyze the risks 
for outcomes associated with the interaction between baseline viral serostatus and sirolimus 




Figure 5 depicts that compared with control, most sirolimus regimen-viral serostatus interactions 
were associated with statistically higher risks for patent death in 5 years, except in: SRL regimen 
in HCV+ KTR [(SRL+MPA: HR=1.50, 95% CI=0.93-2.26), (SRL+Tac: HR=1.41, 95% 
CI=0.84-2.27)]; SRL+MPA in HBc+ KTR (HR=1.38, 95%CI=0.84-2.25) and SRL+Tac in EBV- 
KTR (HR=1.41, 95%CI=0.96-2.06). 
 
Death-censored graft loss risk 
Regardless of concomitant pretansplant viral serostatus, most sirolimus regimens were associated 
with higher risk for DCGL than control except with SRL+Tac in HBc+, HCV+, and CMV- 
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Post-transplant malignancy risk, censored for death or graft-loss  
Relative to the reference regimen (Tac+MPA), the 5-year risk of posttransplant malignancy 
(PTM) was lower with SRL+MPA, not SRL+Tac in KTR with HBc-, HCV-, EBV- or CMV- 
serostatus pre-transplant; (Fig. 7). The highest de novo PTM risk reduction point estimate of 73 
% was seen in EBV- recipients on SRL+MPA (HR=0.27, 95% CI=0.10-0.72), followed by 39% 
in CMV- recipients on SRL+MPA (HR=0.61, 95% CI=0.43-0.88). No risk reduction for PTM 
was seen in KTR with positive viral serostatus pretransplant and placed on either SRL+MPA or 
SRL+Tac (Figure 7). 
 
Outcomes in KTR with sirolimus use at other periods in first transplant year  
 In KTR who received SRL+MPA or SRL+Tac within the first transplant year, albeit outside of 
the study periods above; the adjusted relative risk for death was 3 times higher in KTR on 
SRL+MPA at discharge and 6
th
 month follow-up only compared with KTR on SRL+MPA or 
SRL+Tac in the study periods, [HR=4.29, 95% CI=2.31-7.97 vs. HR=1.41, 95% CI=1.23-1.60 or 
HR=1.53, 95% CI=1.35-1.74, respectively], [Figure 8]. Due to database and sample size 




Our study of 62 315 adult recipients of kidney transplants over a 14-year period based on the 
United States SRTR focused on the association between 5-year transplant outcomes and baseline 
Hepatitis B core, Hepatitis C, CMV and EBV serostatus of kidney allograft recipients with 1-
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more months immediately before and including the first transplant year anniversary. We also 
examined factors predictive of the sustained use of sirolimus within the period mentioned. The 
primary results of our study demonstrated that the interaction between pre-transplant viral 
serostatus and posttransplant sirolimus regimen [(SRL+MPA or SRL+Tac) maintained for at 
least 6 months into the first transplant year], were associated with varying posttransplant 
malignancy risks. Negative HBc, HCV, EBV or CMV serostatus was associated with a risk 
reduction for de novo cancer in KTR maintained on SRL+MPA, not SRL+Tac. A positive (HBc, 
HCV, EBV or CMV) serostatus was not associated with a significant difference in de novo 
cancer risk with either SRL regimens, SRL+MPA or SRL+Tac (versus the reference regimen). 
With few exceptions, regardless of their baseline viral serostatus, mortality and graft loss risks 
were higher in KTR maintained on sirolimus regimens compared to those maintained on 
Tac+MPA Our findings could enable the use of pretransplant viral antibody serostatus in the 
decision-making process regarding the use of SRL+MPA, or SRL+Tac, or Tac+MPA as 
maintenance regimen in kidney transplant rejection prophylaxis. For patients already on 
sirolimus regimens, knowledge of the interaction between the specific regimen and baseline viral 
serostatus may help in the prognostication of for transplant outcomes. 
 
The overall Cox model for including all 62 315 recipients showed that sirolimus-containing 
regimens were associated with higher risks of patient death. This is consistent with the findings 
in a meta-analysis that included 21 randomized controlled trials with 5963 patients [35]. In that 
report, any sirolimus regimen was associated with a 43% increased risk of death; whereas, in our 
current retrospective study involving 4826 patients, stratified analysis of sirolimus regimens 





Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
16 
 
SRL+Tac, and by 37% with SRL+MPA. Due to database limitation, we were unable to test 
whether the prodiabetic, prodyslipidemic, and nephrotoxic complications of the combined 
SRL+Tac regimen could have contributed to the higher mortality in KTR treated with the 
regimen especially in the HCV-positive KTR [31, 42-55]. Our findings in kidney transplants are 
consistent with the finding of Wagner et al. in liver transplants wherein SRL+MPA was 
associated with a more favorable outcome than SRL+Tac in HCV+ patients  
 [Figure 5], [53]. In another study, Luan, et al showed that in HCV seropositive KTR, 
mycophenolate lowered, while tacrolimus seemed to have increased the risk for patient mortality 
[16]. The reduced risk of mortality associated with a positive CMV or EBV serostatus in the 
main Cox model was likely driven by the large size of the Tac+MPA cohort which comprised 
92% of the sample [Table 1]. This is supported by the stratified Cox analyses results that showed 
lower mortality risk with Tac+MPA than with any of the sirolimus regimens regardless of the 
concomitant CMV or EBV serostatus of the KTR [Fig. 1]. 
 
The main Cox models showed that the 2 sirolimus regimens were associated with a higher risks 
of death-censored graft loss than Tac+MPA. The Cox models with interactions showed that 
regardless of the viral serostatus of KTR, SRL-containing regimens were as sociated with higher 
risk of graft loss than Tac+MPA; except with SRL+Tac in HBc+ or HCV+ KTR. With the recent 
introduction of more efficacious regimens for HCV treatment, the implications of our findings 
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According to our analysis of the CONVERT trial adverse reaction data [57], sirolimus regimens 
were associated with a lower risk of malignancy versus non-sirolimus regimens at the 2-year 
follow-up [crude risk ratio 0.35, (95% CI=0.20-0.59)]. A retrospective database analysis by 
Kauffman, et.al. showed that sirolimus was associated with a de novo cancer risk reduction of 
0.39 (95% CI=0.24-0.64), [32]. In our study, the risk reduction for cancer was significant at 20% 
for SRL+MPA but not for SRL+Tac [(SRL+MPA: HR=0.80, 95% CI=0.65-0.98) and 
(SRL+TAC:HR=0.82, 95%CI=0.65-1.03)]. Our study differed from the 2 preceding studies in its 
larger sample size, its stratification of SRL regimens into SRL+MPA and SRL+Tac, and its 
analysis of interactions between SRL and viral serology. Compared to the study of Kauffman et 
al., we analyzed outcomes based on longitudinal immunosuppression data at 3 points after 
transplant and not on discharge information alone and we studied SLR+MPA, not SRL+ 
calcineurin inhibitor only [17]. 
 
We have found a significantly higher risk of death in KTR who were on sirolimus at discharge 
and 6th month (but the regimen was not successfully continued to the 12
th
 month of transplant) 
compared with KTR whose SRL regimens were successfully continued to the 12
th
 month of 
transplant after initial use at or before discharge or 6
th
 month follow-up [Figure 8]. As the 
factors that affected the decision to discontinue the sirolimus regimens were not reported in 
SRTR, we can only hypothesize that discontinuation of sirolimus regimens may have indicated 
complications and/or poor patient conditions that increased the risk of death. 
 
Our study provides a unique perspective in the consideration of sirolimus regimens in kidney 
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interactions between the baseline viral serostatus and posttransplant SRL regimens of KTR. Our 
study limitations include those inherent in an observational analysis [58], and lack of information 
on the following: tacrolimus and sirolimus blood levels, incidence of posttransplant viral 
infections and treatment given. Due to the underreporting of specific malignancy types to SRTR 
(59), we used the standard analysis files’ aggregated data on de novo malignancy and PTLD. 
Therefore, our report cannot provide sufficiently powered analyses on the relationships between 
specific malignancy types, sirolimus regimens and transplant outcomes. Despite its 
shortcomings, we used the SRTR as our data source relying on the established acceptance of this 
database in well-regarded transplantation publications (10, 21,32, 39, 60). 
 
In conclusion, our retrospective study demonstrated that compared with standard Tac+MPA 
immunosuppression, the lower risk of malignancy associated with sirolimus regimen is seen with 
SRL+MPA, not with SRL+Tac in KTR with negative pretransplant antibody serology to Hbc, 
HCV, EBV or CMV; neither sirolimus regimen was associated with a different malignancy risk 
in KTR with positive pretransplant antibody serology to any of the foregoing viruses. With a few 
exceptions, a sirolimus-containing regimens were associated with higher risks of patient death 
and death-censored graft loss than the Tac+MPA regimen regardless of the recipient’s baseline 
viral serostatus. Our findings may be informative in planning posttransplant immunosuppression 
with sirolimus-containing regimens and in prognosticating 5-year outcomes in KTR already 










The data reported here have been supplied by the Minneapolis Medical Research Foundation as 
the contractor for the SRTR. The interpretation and reporting of these data are the responsibility 
of the authors and in no way should be seen as an official policy of or interpretation by the SRTR 










1. Weikert BC, Blumberg EA. Viral infection after renal transplantation: surveillance and 
management. Clin J Am Soc Nephrol. 2008 ;3 Suppl 2: S76–86. 
2. Cukuranovic J, Ugrenovic S, Jovanovic I, Visnjic M, Stefanovic V. Viral infection in renal 
transplant recipients. Scientific World Journal. 2012; 2012:820621 
3. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol. 
2005 ;16(6):1758–74. 
4. Boubenider S, Hiesse C, Marchand S, Hafi A, Kriaa F, Charpentier B. Post-transplantation 
polyomavirus infections. J Nephrol. 1999;12(1):24–9. 
5. Sagedal S, Nordal KP, Hartmann A, , et al. The impact of cytomegalovirus infection and 
disease on rejection episodes in renal allograft recipients. Am J Transplant. 2002 Oct; 
2(9):850–6. 
6. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ 
transplant recipients: a systematic review. Drugs. 2007; 67(8):1167–98. 
7. Desai R, Collett D, Watson CJE, Johnson PJ, Moss P, Neuberger J. Impact of 
Cytomegalovirus on Long-term Mortality and Cancer Risk After Organ Transplantation. 
Transplantation. 2015 Sep; 99(9):1989–94. 
8. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and 
disease on long-term recipient and kidney graft survival. Kidney Int. 2004 Jul; 66(1):329–
37. 






Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
21 
 
10. Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche H-U. Associations between EBV 
serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National 
Registry Data in the United States. Am J Transplant. 2012 ; 12(4):976–83. 
11. Shahinian VB, Muirhead N, Jevnikar AM, et al. Epstein-Barr virus seronegativity is a risk 
factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft 
recipients. Transplantation. 2003 ; 75(6):851–6. 
 12. Bamoulid J, Courivaud C, Coaquette A, et al. Subclinical Epstein-Barr virus viremia among 
adult renal transplant recipients: incidence and consequences. Am J Transplant. 2013 ; 
13(3):656–62. 
13. Lezaic V, Visnja L, Stosovic M, et al. Hepatitis B and hepatitis C virus infection and 
outcome of hemodialysis and kidney transplant patients. Ren Fail. 2008; 30(1):81–7. 
14. O’ Riordan, A, Agarwal, K, Kon, S, Macdougall, I, Donohoe. Reactivation of hepatitis B 
virus infection in renal transplant recipients. 
www.britishrenal.org/BritishRenalSociety/files/2e/2e809ba0-f18e accessed 3/7/2016. 
15. Lin H-H, Huang C-C, Huang J-Y, et al. Impact of HCV infection on first cadaveric renal 
transplantation, a single center experience. Clin Transplant. 2004 ; 18(3):261–6. 
16. Luan FL, Schaubel DE, Zhang H, et al. Impact of immunosuppressive regimen on survival of 
kidney transplant recipients with hepatitis C. Transplantation. 2008 Jun 15; 85(11):1601–6. 
17. Morton LM, Gibson TM, Clarke CA, Lynch CF, Weisenburger DD, Engels EA. Hepatitis B 
or C virus infection and risk of non-Hodgkin lymphoma among solid organ transplant 
recipients. Haematologica. 2014 May; 99(5):70–3. 
18. Morath C, Arns W, Schwenger V, et al. Sirolimus in renal transplantation. Nephrol Dial 





Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
22 
 
19. Gatault P, Lebranchu Y. Conversion to mTOR-inhibitor-based immunosuppression: which 
patients and when? Transplant Res. 2013 ; 2(Suppl 1): S3. 
20. González E, Andrés A, Polanco N, et al. Everolimus represents an advance in 
immunosuppression for patients who have developed cancer after renal transplantation. 
Transplant Proc. 2009 ; 41(6):2332–3. 
21. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant 
malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004 ; 
4(1):87–93. 
22. Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal 
transplantation: the University of Texas at Houston experience. Transplant Proc. 2003 ; 
35(3 Suppl):25S – 34S. 
23. Shertz CA, Cardenas ME. Exploiting and subverting Tor signaling in the pathogenesis of 
fungi, parasites, and viruses. PLoS Pathog. 2011 Sep; 7(9): e1002269. 
24. Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr 
Opin Organ Transplant. 2008; 13(6):563–8. 
25. Luan FL, Hojo M, Maluccio M, et al. Rapamycin Blocks Tumor Progression: Unlinking 
Immunosuppression from Antitumor Efficacy. Transplantation 2002; 73: 1565-72. 
26. Back JH, Kim AL. The expanding relevance of nuclear mTOR in carcinogenesis. Cell Cycle. 
2011 Nov 15; 10(22):3849–52. 
27. Koehl GE, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while 






Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
23 
 
28. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005 ; 
56(1):47–60. 
29. Belliere J, Kamar N, Mengelle C, et al. Pilot conversion trial from mycophenolic acid to 
everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or 
viremia. Transpl Int. 2016 Mar; 29(3):315–22. 
30. Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M. Hepatitis C virus 
infection and kidney transplantation in 2014: what’s new? Am J Transplant. 2014 Oct; 
14(10):2206–20. 
31. Brennan DC, Aguado JM, Potena L, Jardine AG, Legendre C, Säemann MD, et al. Effect of 
maintenance immunosuppressive drugs on virus pathobiology: evidence and potential 
mechanisms. Rev Med Virol. 2013 ; 23(2):97–125. 
32. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance 
immunosuppression with target-of-rapamycin inhibitors is associated with a reduced 
incidence of de novo malignancies. Transplantation. 2005 ; 80(7):883–9. 
33. Yanik EL, Gustafson SK, Kasiske BL, et al. Sirolimus use and cancer incidence among US 
kidney transplant recipients. Am J Transplant. 2015 ; 15(1):129–36. 
34. Gatault P, Lebranchu Y. Conversion to mTOR-inhibitor-based immunosuppression: which 
patients and when? Transplant Res. 2013 ; 2(Suppl 1): S3. 
35. Flechner S, Friend P, Campistol J, Weir M, Diekmann F, Russ G. De novo 
immunosuppression with mammalian target of rapamycin inhibitors and posttransplantation 





Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
24 
 
36. Bagley SC, White H, Golomb BA. Logistic regression in the medical literature: standards for 
use and reporting, with particular attention to one medical domain. Clin Epidemiol. 2001; 
54: 979–985. 
37. Kasiske, B, Snyder J, Gilbertson D, Wang C. Cancer after kidney transplantation in the 
United States. Am J Transplant. 2004; 4:905-913. 
38. Ju MK, J DJ, Kim SJ, et al. Chronologically different incidences of post-transplant 
malignancies in renal transplant recipients: single center experience. Transplant 
International. 2009; 2(6): 644-653. 
39. Cherikh Ws, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. 
Association of the type of induction immunosuppression with posttransplant 
lymphoproliferative disorder, graft survival, and patient survival after primary kidney 
transplantation. Transplantation 2003 ; 76(9): 1289-1293. 
40. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO 
clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 
2009; 9 (Suppl 3): S1–S157. 





42. Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival after 
kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 





Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
25 
 
43. Subherwal S, Patel MR, Kober L, et al. Peripheral artery disease is a coronary heart disease 
risk equivalent among both men and women: results from a nationwide study. Eur J Prev 
Cardiol. 2015 ;22(3):317-25. 
44. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease 
among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol. 
2001; 12(7):1516–23. 
45. den Dekker MAM, van den Dungen JJ a. M, Tielliu IFJ, Tio RA, et al. Prevalence of severe 
subclinical coronary artery disease on cardiac CT and MRI in patients with extra-cardiac 
arterial disease. Eur J Vasc Endovasc Surg. 2013; 46(6):680–9. 
46. Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, 
and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009; 
69(16):2227–43. 
47. Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV. Association of 
immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder 
in kidney transplant recipients. Transplantation. 2012 ; 93(1):73–81. 
48. Murakami N, Riella LV, Funakoshi T. Risk of metabolic complications in kidney 
transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. 
Am J Transplant. 2014 Oct; 14(10):2317–27. 
49. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes 
in kidney transplant recipients. J Am Soc Nephrol. 2008 Jul; 19(7):1411–8. 
50. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes 




Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
26 
 
51. Antonelli A, Ferri C, Fallahi P, et al. Hepatitis C virus infection: evidence for an association 
with type 2 diabetes. Diabetes Care. 2005 ; 28(10):2548–50. 
52. Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N and Tomer Y (2015) Diabetes 
and hepatitis C: a two-way association. Front. Endocrinol. 6:134. doi: 
10.3389/fendo.2015.00134 
53. Wagner D, Kniepeiss D, Silvia S, et al Sirolimus has a potential to influent viral recurrence 
in HCV positive liver transplant candidates. Int Immunopharmacol. 2010 ;10(8):990-3. 
54. Bloom RD, Lake JR. Emerging issues in hepatitis C virus-positive liver and kidney 
transplant recipients. Am J Transplant. 2006 ; 6(10):2232–7. 
55. Larson TS, Dean PG, Stegall MD, et al Complete avoidance of calcineurin inhibitors in renal 
transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 
2006, 6:514-52. 
56. Weikert BC, Blumberg EA. Viral infection after renal transplantation: surveillance and 
management. Clin J Am Soc Nephrol. 2008 ; 3 Suppl 2: S76–86. 
57. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, et al. Conversion from calcineurin 
inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy 
and safety results from the CONVERT trial. Transplantation. 2009 ; 87(2):233–42.  
58. Kaplan B, Schold J, Meier-Kriesche H-U. Overview of large database analysis in renal 
transplantation. Am J Transplant. 2003 ; 3(9):1052–6 
59. Yanik EL, Nogueira LM, Koch L, et al. Comparison of cancer diagnoses between the US 
solid organ transplant registry and linked central cancer registries. [published online ahead 
of print April 7
th





Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
27 
 
60. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset 
post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J 










Figure 1. 5-Year Patient Mortality, Main Cox Model 
Figure 2. 5-Year Death-Censored Graft Loss, Main Cox Model 
Figure 3. 5-Year Malignancy Risk Factors, Main Cox Model 
Figure 4. 5-Year Cause Specific Crude Death Rates in Cohorts with 1 Year Conditional 
Survival 
Figure 5. 5-Year Risk for Patient Death, Viral Serostatus-Sirolimus Interaction Cox 
Models 
Figure 6. 5-Year Risk for Death-Censored Graft Loss, Viral Serostatus-Sirolimus 
Interaction Cox Models 
Figure 7. 5-Year Risk for Malignancy, Viral Serostatus-Sirolimus Interaction Cox Models 
Figure 8. 5-Year Outcomes Associated with Different Durations of Sirolimus Regimen Use 


















































































Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
37 
 
TABLE I. Demographic and Clinical Characteristics of US Adult Kidney Transplants 
Recipients from 2000 through 2013 comprising the 3 immunosuppression cohorts, N=61 
590 
 
    











Pretransplant Viral Serology: 
Hepatitis B antibody + 
Hepatitis C antibody + 











 1381 (63.7) 
   
  4426 (7.8) 









Expanded Criteria Deceased 

















Donor Age, years: Mean (SD) 41.8 (14.6) 38.1 (14.8) 38.7 (14.7) <.001 
Recipient Age, years: Mean (SD) 48.7 (13.4) 46.2 (13.6) 49.3 (13.7) <.001 
Recipient Race:  
     Black 













Recipient Gender:  
      Male 













Previous Kidney Transplant: 
       Yes 













Recipient BMI: > = 30 kg/m2 807 (31.9) 522 (25.6) 17797 (32.7) <.001 
CAD or CAD-equivalent b 414 (15.6) 245 (11.3) 6728 (11.8) <.001 
Pretransplant PRA: PRA >/= 20% 565 (21.2) 520 (24.0) 15269 (26.9) <.001 
HLA mismatch > 3 1501 (63.6) 1193 (60.9) 33756 (65.9) <.001 





























Pretransplant Dialysis History: 









Transplant Year:  
      2000- 2009 











Steroids in Regimen: 1818 (68.4) 1418 (65.4) 38782 (68.3) .02 





























Based on Scientific Registry of Transplant Recipients Immunosuppression Records Collected at 
discharge, month-6 and month-12 follow-up, recipients were on same regimen with or without 
steroids at discharge, 6
th
 month and 12
th
 month or at 6
th




CAD=Coronary Artery Disease including angina or coronary artery disease. CAD-equivalent 
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TABLE 2. Adjusted Odds Ratio for Continuous Sirolimus Regimen Use for A Minimum of 
6 Months Immediately Before and Including the Twelfth Transplant Month in Adult 
Kidney Allograft Recipients 
 
    
Predictor Variable (Reference) 
SRL + MPA vs. 
Tac+ MPA 
 
 HR  95% CI 
SRL + Tac vs. 
Tac + MPA 
 
 HR  95% CI 
SRL +MPA vs. 
SRL + Tac 
 
 HR  95% CI 
Pretransplant Viral Serology: 
Hepatitis Bc antibody + (-) 
Hepatitis C antibody + (-) 
Epstein Barr Virus + (-) 
Cytomegalovirus + (-) 
 
0.83 [0.70 0.99] 
1.02 [0.83 1.25] 
1.12 [0.98 1.28] 
0.82 [0.75 0.90] 
 
0.98 [0.82 1.17] 
0.84 [0.66 1.07] 
1.10 [0.95 1.27] 
0.95 [0.85 1.05] 
 
0.87 [0.68 1.12] 
1.23 [0.90 1.70] 
1.00 [0.82 1.22] 





1.63 [1.40 1.89] 
0.90 [0.81 0.99] 
 
1.18 [0.98 1.42] 
0.99 [0.88 1.10] 
 
1.35 [1.07 1.71] 
0.88 [0.76 1.03] 
Recipient Age   0.99 [0.99 0.998] 0.987 [0.98 0.99] 1.01 [1.00 1.014] 
Recipient Race: Black (Other) 1.13 [1.02 1.26] 1.12 [1.00 1.25] 0.98 [0.84 1.14] 
Recipient Sex: Female (Male) 0.85 [0.77 0.93] 1.07 [0.97 1.18] 0.80 [0.70 0.92] 
Previous Kidney Transplant: + (- ) 0.90 [0.76 1.06] 1.25 [1.07 1.46] 0.74 [0.60 0.93] 
Recipient BMI: >30(<30) kg/m2 0.99 [0.90 1.09] 0.83 [0.75 0.93] 1.18 [1.02 1.36] 
>1 CAD or CAD-equivalent c 1.26 [1.11 1.43] 0.91 [0.78 1.07] 1.32 [1.08 1.61] 
PRA: PRA >20% (<20%) 0.87 [0.78 0.98] 0.88 [0.78 1.00] 0.97 [0.82 1.15] 
HLA mismatch > 3 (<3) 0.95 [0.86 1.04] 0.88 [0.79 0.97] 1.08 [0.93 1.24] 





1.01 [0.85 1.19] 
0.96 [0.81 1.14] 
1.13 [0.96 1.33] 
 
0.90 [0.75 1.08] 
0.87 [0.73 1.04] 
0.91 [0.76 1.09] 
 
1.17 [0.91 1.50] 
1.13 [0.89 1.45] 
1.26 [0.98 1.61] 
On dialysis (pre-emptive transp.) 0.98 [0.86 1.10] 1.10 [0.96 1.26] 0.92 [0.77 1.11] 





0.92 [0.83 1.02] 
0.43 [0.35 0.54] 
 
0.90 [0.80 1.01] 
0.15 [0.10 0.23] 
 
0.96 [0.82 1.12] 
2.31 [1.41 3.76] 
 
SRL+MPA, sirolimus and mycopneolate; SRL+Tac, sirolimus and tacrolimus; Tac+MPA, 
tacrolimus and mycophenolate;  
a
ECD, Expanded Criteria Deceased 
 
b









CAD=Coronary Artery Disease including angina or coronary artery disease. CAD-equivalent 
included Diabetes Mellitus, Peripheral Vascular Disease and Cerebro-vascular disease 
AC
CE
PT
ED
